Zacks Research upgraded shares of Relay Therapeutics (NASDAQ:RLAY – Free Report) from a strong sell rating to a hold rating in a research note released on Thursday,Zacks.com reports.
Several other research analysts have also recently weighed in on the stock. Oppenheimer boosted their price target on shares of Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Monday, July 6th. JonesTrading raised shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Barclays boosted their target price on Relay Therapeutics from $27.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Canaccord Genuity Group started coverage on Relay Therapeutics in a report on Thursday, July 16th. They issued a “buy” rating and a $29.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.92.
Relay Therapeutics Price Performance
Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The firm had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.96 million. As a group, equities analysts anticipate that Relay Therapeutics will post -1.6 EPS for the current year.
Insider Activity at Relay Therapeutics
In related news, CFO Thomas Catinazzo sold 1,459 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total value of $27,151.99. Following the transaction, the chief financial officer owned 158,285 shares in the company, valued at approximately $2,945,683.85. This represents a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sanjiv Patel sold 48,199 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $19.58, for a total value of $943,736.42. Following the transaction, the chief executive officer directly owned 615,898 shares of the company’s stock, valued at approximately $12,059,282.84. This trade represents a 7.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 409,639 shares of company stock worth $7,233,399. 5.04% of the stock is currently owned by company insiders.
Institutional Trading of Relay Therapeutics
Hedge funds have recently made changes to their positions in the company. Torren Management LLC purchased a new position in shares of Relay Therapeutics during the 4th quarter valued at $30,000. KBC Group NV purchased a new stake in Relay Therapeutics in the 1st quarter worth about $34,000. Allworth Financial LP purchased a new stake in Relay Therapeutics in the 2nd quarter worth about $34,000. Smartleaf Asset Management LLC raised its stake in Relay Therapeutics by 288.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after acquiring an additional 3,287 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Relay Therapeutics in the 4th quarter valued at about $46,000. 96.98% of the stock is currently owned by institutional investors.
Key Relay Therapeutics News
Here are the key news stories impacting Relay Therapeutics this week:
- Positive Sentiment: HC Wainwright raised its price target to $29 from $28 and maintained a “Buy” rating. The target implies substantial potential upside from the $19.44 reference price, providing a positive valuation signal for RLAY. Benzinga
- Positive Sentiment: Zacks Research upgraded Relay Therapeutics from “Strong Sell” to “Hold.” Although not a bullish recommendation, the upgrade removes a strongly negative rating and may modestly improve investor sentiment. Zacks Research rating update
- Neutral Sentiment: HC Wainwright’s quarterly forecasts call for ongoing losses, ranging from $0.39 to $0.41 per share through 2027, while its FY2027 estimate is a $1.60-per-share loss. The firm nevertheless reiterated its Buy rating and $29 target, indicating that its thesis likely depends on future pipeline progress rather than near-term profitability. MarketBeat analyst estimates
- Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate to a $1.57 loss from a $1.50 loss and reduced its Q3 2026 estimate to a $0.37 loss from $0.36. Its Q4 estimate also fell to a $0.38 loss from $0.37, pointing to slightly weaker expected near-term results. MarketBeat forecast revisions
- Negative Sentiment: Relay Therapeutics’ latest reported quarter missed expectations, with EPS of negative $0.41 versus a consensus negative $0.39 and revenue of $0.35 million versus an expected $0.96 million. The shortfall may weigh on confidence in the company’s near-term execution. Relay Therapeutics Q2 results
About Relay Therapeutics
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
Featured Stories
- Five stocks we like better than Relay Therapeutics
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
